Abbott aids biotech Epizyme in matching epigenetic drug with cancer patients

Ryan McBride Abbott ($ ABT) plans to develop a companion diagnostic test for an experimental leukemia drug from the biotech startup Epizyme. The agreement follows the start of a Phase ...

Supreme Court exposes GlaxoSmithKline to Humana’s Avandia-spending claims

Tracy Staton The U.S. Supreme Court declined to consider an appeal from GlaxoSmithKline ($ GSK) in a fight over Humana's spending on the company's disgraced diabetes drug ...

FDA seeks more data from Sarepta to decide on accelerated approval

Ryan McBride Sarepta Therapeutics ($ SRPT) has kept hopes alive for gaining accelerated approval for its lead drug eteplirsen for Duchenne muscular dystrophy. Yet the FDA wants additional ...

1 Stem-Cell Spinout You Must Watch

By Brian Orelli Nearly a year after Geron (Nasdaq: GERN  ) said it wasshuttering its stem cell program, the biotech has a buyer if it wants. Buyer being a relative term. BioTime (NYSEMKT: BTX  ) agreed ...

BioTime makes offer for Geron stem cell assets

BioTime sends letter to Geron shareholders making offer for company’s stem cell therapies NEW YORK (AP) — Biotechnology company BioTime Inc. on Thursday proposed two transactions ...

Gene therapy pioneers tackle macular degeneration

By John Carroll An Ann Arbor, MI-based biotech start-up has gained some high-profile attention for its work on a new gene therapy approach for eye diseases. MIT’s Technology ...

Stem cell biotech Fate nails down $9.2M

By Ryan McBride Fate Therapeutics has pieced together a $9.2 million round of equity financing, according to an SEC filing. Based on its knowledge of stem cell biology, the San Diego-based ...

Roche blockbuster Avastin does well as brain tumor therapy

By Eric Palmer Roche Holdings, which is trying to extend the franchise on its blockbuster cancer medication Avastin, reported a new study that offers hope for some patients with brain ...

Pluristem soars after stem cell drug aids recovery of cancer patient

By Ryan McBride Pluristem Therapeutics ($PTSI) delivered news yesterday about how the developer’s placental stem cell treatment helped a cancer patient recover from potentially ...

Pluristem stem cell therapy saves woman with bone marrow failure

This was the second successful treatment of a patient with bone marrow failure in three months, under Israeli government compassionate use protocols. The share price of Pluristem Therapeutics ...

Histogenics reels in $49M Series A for tissue engineering implants

By John Carroll Histogenics–a tissue engineering company–has nailed down $49 million in new Series A financing intended to bring its two signature products to the regulatory ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS